Allogene Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 12, 2026

ALLO$1.06+1.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Collaboration revenue - related party	$4,640	$—	$4,640	$—
Operating expenses:
Research and development	30,721	40,156	62,724	90,356
General and administrative	20,839	14,281	34,928	29,272
Impairment of long-lived assets	—	2,382	—	2,382
Total operating expenses	51,560	56,819	97,652	122,010
Loss from operations	(46,920)	(56,819)	(93,012)	(122,010)
Other income (expenses), net:
Interest and other income, net	4,647	6,187	8,220	11,703
Interest expense	(343)	(268)	(643)	(418)
Other income (expenses), net	(61)	(43)	151	49
Total other income (expenses), net	4,243	5,876	7,728	11,334
Net loss	(42,677)	(50,943)	(85,284)	(110,676)
Other comprehensive income (loss):
Net unrealized gain (loss) on available-for-sale investments	(335)	(88)	(787)	44
Net comprehensive loss	$(43,012)	$(51,031)	$(86,071)	$(110,632)
Net loss per share, basic and diluted	$(0.13)	$(0.23)	$(0.30)	$(0.51)
Weighted-average number of shares used in computing net loss per share, basic and diluted	328,930,269	218,929,548	284,855,386	217,153,948

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.